drugset / Trial / NCT06692933
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
Phase 0
Recruiting
24 enrolled
Washington State University
National Center for Complementary and Integrative Health (NCCIH) · collabOffice of Dietary Supplements (ODS) · collab
Non-randomizedCrossoverOpen-labelBasic science
Summary
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Timeline
- Start
- 2024-06-20
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 30 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 240 mg | Oral |
| Subject | Clopidogrel | Small molecule | 75 mg | Oral |
Indications
No indication recorded.